Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial
Zöhrer E, Alisi A, Jahnel J, Mosca A, Della Corte C, Crudele A, Fauler G, Nobili V
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 58 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-05-16 · Appl Physiol Nutr Metab · vol. 42 · número 9 · págs. 948–954
- Editorial
- NRC Research Press
- Citado
- 74 citas · más que el 96% de estudios similares · 4.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Liver Disease and Transplantation · Pancreatitis Pathology and Treatment
- Palabras clave
- Nonalcoholic fatty liver disease, Internal medicine, Steatosis, Docosahexaenoic acid, Placebo, Medicine, Gastroenterology, FGF19, Liver biopsy, Randomized controlled trial, Nonalcoholic steatohepatitis, Choline, Fatty liver, Ursodeoxycholic acid, Endocrinology, Polyunsaturated fatty acid, Biopsy, Biochemistry, Fatty acid, Disease, Biology, Pathology, Fibroblast growth factor
- MeSH
- liver, humans, disease progression, choline, vitamin e, docosahexaenoic acids, biopsy, combined modality therapy, exercise, severity of illness index, follow-up studies, double-blind method, dietary supplements, adolescent, child, female, male, child nutritional physiological phenomena, non-alcoholic fatty liver disease, biomarkers, healthy lifestyle
8 autores
- Evelyn Zöhrer🇦🇹 · autor de correspondenciaMedical University of Graz
- Anna Alisi🇮🇹 · autor de correspondenciaBambino Gesù Children's Hospital
- Jörg Jahnel🇦🇹Medical University of Graz
- Antonella Mosca🇮🇹Bambino Gesù Children's Hospital
- Claudia Della Corte🇮🇹Bambino Gesù Children's Hospital
- Annalisa Crudele🇮🇹Bambino Gesù Children's Hospital
- Günter Fauler🇦🇹Medical University of Graz
- Valerio Nobili🇮🇹Bambino Gesù Children's Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease, is one of the most common hepatic diseases in children. We conducted a randomized controlled clinical trial on children with biopsy-proven NASH based on a combinatorial nutritional approach compared with placebo. Participants were assigned to lifestyle modification plus placebo or lifestyle modification plus a mix containing docosahexaenoic acid, choline, and vitamin E (DHA-CHO-VE). Forty children and adolescents participated in the entire trial. The primary outcome was the improvement of liver hyperechogenicity. Secondary outcomes included alterations of alanine aminotransferase (ALT) and other metabolic parameters. Furthermore, changes of serum bile acids (BA) and plasma fibroblast growth factor 19 (FGF19) levels were evaluated as inverse biomarkers of disease severity. At the end of the study, we observed a significant decrease in severe steatosis in the treatment group (50% to 5%, p = 0.001). Furthermore, although the anthropometric and biochemical measurements in the placebo and DHA-CHO-VE groups were comparable at baseline, at the end of the study ALT and fasting glucose levels improved only in the treatment group. Finally, we found that BA levels were not influenced whereas FGF19 levels were significantly increased by DHA-CHO-VE. The results suggest that a combination of DHA, VE, and CHO could improve steatosis and reduce ALT and glucose levels in children with NASH. However, further studies are needed to assess the impact of a DHA and VE combination on repair of liver damage in paediatric NASH.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.